Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The Cambridge-based company is targeting the DNA Damage Response (DDR) pathway to attack various cancers.
The companies will co-finance a clinical study to test the combination of SHP2 inhibitor BBP-398 and OPDIVO in treating patients with advanced solid tumors KRAS mutations.
Bryan Dechairo, newly appointed president and CEO of Sherlock Biosciences, learned early to fill gaps and seize opportunities. Read more about his views.
Kodiak Sciences, an ophthalmology-focused biotech company, based in Palo Alto, Calif., reportedly turned down $125 million from Baker Bros after hitting a clinical milestone. The company’s decision to decline this funding was due in part to its “strong balance sheet” and “clinical trial progress.”
Lantern will reacquire the Irofulven program and evaluate its potential for advanced development to treat bladder and prostate cancers.
It’s been a long season of acquisitions for PerkinElmer. Now in its largest purchase ever, the Massachusetts-based company is dropping a massive $5.25 billion in cash and stock to buy biomedical research tool company BioLegend.
As disgraced Theranos founder Elizabeth Holmes awaits her day in court, a long-awaited documentary series focused on the Stanford dropout who became a billionaire before losing it all is set to air on streaming service Hulu.
Phase one launched last week after patients who had been on placebo in Biogen’s pivotal phase III VALOR study were transitioned to active therapy.
The company also issued an open letter to the Alzheimer’s disease community from Alfred Sandrock, which attempts to push back against negative media attention.
Merck’s former chief executive officer and current executive chairman, Kenneth Frazier, has stepped down from his post at the pharmaceutical company to join venture capital firm General Catalyst as its newest chairman of health assurance initiatives.